NutraLife BioSciences, Inc.
NLBS · OTC
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $2 | $4 |
| % Growth | -50.1% | -41.1% | -42.5% | – |
| Cost of Goods Sold | $1 | $1 | $2 | $2 |
| Gross Profit | $0 | $1 | $1 | $2 |
| % Margin | 13.3% | 40.6% | 28% | 40.4% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $4 | $2 | $4 | $3 |
| SG&A Expenses | $4 | $2 | $4 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $5 | $2 | $4 | $3 |
| Operating Income | -$4 | -$2 | -$3 | -$2 |
| % Margin | -713.8% | -157.1% | -159.1% | -51.4% |
| Other Income/Exp. Net | -$1 | -$1 | -$1 | -$0 |
| Pre-Tax Income | -$6 | -$3 | -$4 | -$2 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$6 | -$3 | -$4 | -$2 |
| % Margin | -930% | -230.1% | -187.8% | -55.9% |
| EPS | -0.04 | -0.02 | -0.036 | -0.024 |
| % Growth | -102% | 45% | -51.3% | – |
| EPS Diluted | -0.04 | -0.02 | -0.036 | -0.024 |
| Weighted Avg Shares Out | 165 | 146 | 113 | 87 |
| Weighted Avg Shares Out Dil | 165 | 146 | 113 | 87 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $2 | $1 | $1 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$4 | -$2 | -$4 | -$2 |
| % Margin | -582.8% | -125.7% | -176.6% | -50.5% |